Jiangsu Hengrui Medicine Co Ltd (600276) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jiangsu Hengrui Medicine Co Ltd (600276) has a cash flow conversion efficiency ratio of 0.080x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥4.81 Billion ≈ $703.99 Million USD) by net assets (CN¥60.03 Billion ≈ $8.78 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Jiangsu Hengrui Medicine Co Ltd to measure how much of total assets are equity-financed.
Jiangsu Hengrui Medicine Co Ltd - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Jiangsu Hengrui Medicine Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 600276 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Jiangsu Hengrui Medicine Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jiangsu Hengrui Medicine Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hangzhou Hikvision Digital Technology Co Ltd
SHE:002415
|
0.088x |
|
Rockwell Automation Inc
NYSE:ROK
|
0.089x |
|
Cencora Inc.
NYSE:COR
|
0.373x |
|
CITIC Securities Co Ltd
SHG:600030
|
0.221x |
|
HOYA CORP. ADR/ 1 O.N.
F:HYB0
|
N/A |
|
Discover Financial Services
NYSE:DFS
|
0.112x |
|
Itaú Unibanco Holding S.A.
SA:ITUB3
|
0.304x |
|
Vistra Energy Corp
NYSE:VST
|
0.281x |
Annual Cash Flow Conversion Efficiency for Jiangsu Hengrui Medicine Co Ltd (1999–2024)
The table below shows the annual cash flow conversion efficiency of Jiangsu Hengrui Medicine Co Ltd from 1999 to 2024. For the full company profile with market capitalisation and key ratios, see Jiangsu Hengrui Medicine Co Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥46.09 Billion ≈ $6.74 Billion |
CN¥7.42 Billion ≈ $1.09 Billion |
0.161x | -13.55% |
| 2023-12-31 | CN¥41.03 Billion ≈ $6.00 Billion |
CN¥7.64 Billion ≈ $1.12 Billion |
0.186x | +465.54% |
| 2022-12-31 | CN¥38.41 Billion ≈ $5.62 Billion |
CN¥1.27 Billion ≈ $185.15 Million |
0.033x | -72.23% |
| 2021-12-31 | CN¥35.57 Billion ≈ $5.21 Billion |
CN¥4.22 Billion ≈ $617.35 Million |
0.119x | +6.39% |
| 2020-12-31 | CN¥30.79 Billion ≈ $4.51 Billion |
CN¥3.43 Billion ≈ $502.20 Million |
0.111x | -27.17% |
| 2019-12-31 | CN¥24.94 Billion ≈ $3.65 Billion |
CN¥3.82 Billion ≈ $558.52 Million |
0.153x | +9.23% |
| 2018-12-31 | CN¥19.80 Billion ≈ $2.90 Billion |
CN¥2.77 Billion ≈ $405.95 Million |
0.140x | -12.30% |
| 2017-12-31 | CN¥15.94 Billion ≈ $2.33 Billion |
CN¥2.55 Billion ≈ $372.76 Million |
0.160x | -20.66% |
| 2016-12-31 | CN¥12.87 Billion ≈ $1.88 Billion |
CN¥2.59 Billion ≈ $379.38 Million |
0.201x | -8.41% |
| 2015-12-31 | CN¥10.36 Billion ≈ $1.52 Billion |
CN¥2.28 Billion ≈ $333.24 Million |
0.220x | +15.77% |
| 2014-12-31 | CN¥8.29 Billion ≈ $1.21 Billion |
CN¥1.57 Billion ≈ $230.37 Million |
0.190x | -7.40% |
| 2013-12-31 | CN¥6.66 Billion ≈ $973.96 Million |
CN¥1.36 Billion ≈ $199.74 Million |
0.205x | +16.46% |
| 2012-12-31 | CN¥5.44 Billion ≈ $796.41 Million |
CN¥958.37 Million ≈ $140.24 Million |
0.176x | +46.20% |
| 2011-12-31 | CN¥4.38 Billion ≈ $640.72 Million |
CN¥527.36 Million ≈ $77.17 Million |
0.120x | +8.44% |
| 2010-12-31 | CN¥3.47 Billion ≈ $508.48 Million |
CN¥385.95 Million ≈ $56.48 Million |
0.111x | -32.59% |
| 2009-12-31 | CN¥2.67 Billion ≈ $389.98 Million |
CN¥439.12 Million ≈ $64.26 Million |
0.165x | +183.99% |
| 2008-12-31 | CN¥2.02 Billion ≈ $296.24 Million |
CN¥117.46 Million ≈ $17.19 Million |
0.058x | -56.71% |
| 2007-12-31 | CN¥1.63 Billion ≈ $238.99 Million |
CN¥218.87 Million ≈ $32.03 Million |
0.134x | -36.72% |
| 2006-12-31 | CN¥1.26 Billion ≈ $183.92 Million |
CN¥266.18 Million ≈ $38.95 Million |
0.212x | +2.98% |
| 2005-12-31 | CN¥1.11 Billion ≈ $162.15 Million |
CN¥227.88 Million ≈ $33.35 Million |
0.206x | -1.99% |
| 2004-12-31 | CN¥998.05 Million ≈ $146.05 Million |
CN¥209.41 Million ≈ $30.64 Million |
0.210x | +38.53% |
| 2003-12-31 | CN¥903.35 Million ≈ $132.19 Million |
CN¥136.82 Million ≈ $20.02 Million |
0.151x | +146.17% |
| 2002-12-31 | CN¥809.97 Million ≈ $118.52 Million |
CN¥49.84 Million ≈ $7.29 Million |
0.062x | +305.99% |
| 2001-12-31 | CN¥757.99 Million ≈ $110.92 Million |
CN¥11.49 Million ≈ $1.68 Million |
0.015x | -48.01% |
| 2000-12-31 | CN¥672.57 Million ≈ $98.42 Million |
CN¥19.61 Million ≈ $2.87 Million |
0.029x | -86.02% |
| 1999-12-31 | CN¥162.54 Million ≈ $23.78 Million |
CN¥33.89 Million ≈ $4.96 Million |
0.208x | -- |
About Jiangsu Hengrui Medicine Co Ltd
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. It develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and… Read more